Scilex Holding Co

Company Profile

• Business description

  Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

• Contact

  960 San Antonio Road
  Palo AltoCA94303
  USA

  T: +1 650 516-4310

  https://www.scilexholding.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Drug Manufacturers - General

  Fiscal Year End

  31 December 2026

  Employees

  34